St. John's wort may ameliorate 2,4,6-trinitrobenzenesulfonic acid colitis of rats through the induction of pregnane X receptors and/or P-glycoproteins

Journal of Physiology and Pharmacology

Volumn 66, Issue 2, 2015, Pages 203-214

  Sehirli, A O ^a   Cetinel, S ^b   Ozkan, N ^a   Selman, S ^a   Tetik, S ^a   Yuksel, M ^a   Dulger, F Gul A ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

2,4,6 trinitrobenzenesulfonic acid; Colitis; Cytochrome P 450; Nuclear factor kappa B; P glycoprotein; Pregnane X receptor; Spironolactone; St. John's wort; Tumour necrosis factor alpha

Indexed keywords

CYTOCHROME P450; HYPERICUM PERFORATUM EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MYELOPEROXIDASE; PREGNANE X RECEPTOR; SPIRONOLACTONE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; PEROXIDASE; PLANT EXTRACT; STEROID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMOLUMINESCENCE; COLITIS; CONTROLLED STUDY; DIARRHEA; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOCHEMISTRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE; INTESTINE INJURY; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; WEIGHT REDUCTION; ANIMAL; BLOOD; CHEMISTRY; COLITIS, ULCERATIVE; DRUG EFFECTS; HYPERICUM; INFLAMMATORY BOWEL DISEASES; METABOLISM; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; COLITIS, ULCERATIVE; CYTOCHROME P-450 ENZYME SYSTEM; HYPERICUM; INFLAMMATORY BOWEL DISEASES; MALE; NF-KAPPA B; OXIDATIVE STRESS; P-GLYCOPROTEINS; PEROXIDASE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, STEROID; SPIRONOLACTONE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927511058     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998; 161: 5733-5744.
2. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003; 52: 759-766.
3. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40.
4. Schwab M, Schaeffeler E, Marx C, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003; 124: 26-33.
5. Shah YM, Ma X, Morimura K, Kim I, Gonzalez FJ. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression. Am J Physiol-Gastr L 2007; 292: G1114-G1122.
6. Mencarelli A, Migliorati M, Barbanti M, et al. Pregnane-Xreceptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells. Biochem Pharmacol 2010; 80: 1700-1707.
7. Iizasa H, Genda N, Kitano T, et al. Altered expression and function of P-glycoprotein in dextran sodium sulfateinduced colitis in mice. J Pharm Sci 2003; 92: 569-576.
8. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006; 130: 341-348.
9. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687-702.
10. Martinez A, Marquez A, Mendoza J, et al. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1484-1487.
11. Di Masie A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspect Med 2009; 30: 297-343.
12. Li JH, Yu JP, Yu HG, Xu XM, Yu LL, Liu SQ. Expression and significance of NF-κB p65 in colon tissues of rats with TNBS-induced colitis. World J Gastroenterol 2005; 11: 1759-1763.
13. Zhou C, Tabb MM, Nelson EL, et al. Mutual expression between steroid and xenobiotic receptor and NF-κB signalling pathways links xenobiotic metabolism and inflammation. J Clin Invest 2006; 116: 2280-2289.
14. Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007; 322: 391-398.
15. Cheng J, Shah YM, Ma X, et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J Pharmacol Exp Ther 2010; 335: 32-41.
16. Suntar IP, Akkol EK, Yilmazer D, et al. Investigations on the in-vivo wound-healing potential of Hypericum perforatum L. J Ethnopharmacol 2010; 127: 468-477.
17. Suntar I, Akkol EK, Keles H, Oktem A, Baser KH, Yesilada E. A novel wound-healing ointment: a formulation of Hypericum perforatum oil and sage and oregano essential oils based on traditional Turkish knowledge. J Ethnopharmacol 2011; 134: 89-96.
18. Dost T, Ozkayran H, Gokalp F, Yenisey C, Birincioglu M. The effect of Hypericum perforatum (St. John's wort) on experimental colitis in rat. Dig Dis Sci 2009; 54: 1214-1221.
19. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St. John's wort, an herbal anti-depressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-R16.
20. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos 2004; 32: 1008-1014.
21. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St. John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500-1504.
22. Perloff MD, von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. St. John's wort: an in-vitro analysis of Pglycoprotein induction due to extended exposure. Brit J Pharmacol 2001; 134: 1601-1608.
23. Durr D, Stieger B, Kullak-Ublick GA, et al. St. John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
24. Guttmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituent may induce intestinal MDR1 and CYP3A4 mRNA expression? Planta Med 2006; 72: 685-690.
25. Schuetz EG, Brimer C, Schuetz JD. Environmental xenobiotics and the anti-hormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP 3A23 hormone response element. Mol Pharmacol 1998; 54: 1113-1117.
26. Toklu HA, Kabasakal L, Imeryuz N, et al. A study comparing the efficacy of anti-microbial agents versus enzyme (P-gp) inducers in the treatment of TNBS colitis of the rats. J Physiol Pharmacol 2013; 64: 439-451.
27. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803.
28. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96: 29-36.
29. Hillegas LM, Griswold DE, Brickson B, Albrightson WC. Assesment of myeloperoxidase activity in whole rat kidney. J Pharmacol Method 1990; 24: 285-295.
30. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 92: 2546-2551.
31. Gnahem CI, Gomez PC, Arana MC, et al. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absoption of orally administered digoxin. J Pharmacol Exp Ther 2006; 318: 1146-1152.
32. Ruiz ML, Villanueva SS, Luquita MG, et al. Induction of intestinal multidrug resistance-associated protein 2 (Mrp2) by spironolactone in rats. Eur J Pharmacol 2009; 623: 103-106.
33. Walhi W. A gut feeling of the PXR, PPAR and NF-κB connection. J Int Medicine 2008; 263: 613-619.
34. Celinski K, Dworzanski T, Fornal R, et al. Comparison of anti-inflammatory properties of peroxisome proliferatoractivated receptor gamma agonists rosiglitazone and trogitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol 2013; 64: 587-595.
35. Blokzijl H, Vander Borght SV, Bok LI, et al. Decreased P glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm Bowel Dis 2007; 13: 710-720.
36. Buyse M, Radev G, Bado A, Farinotti R. Intestinal infammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 2005; 69: 1745-1754.
37. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic anti-depressants in irritable bowel syndrome: a meta-analysis. World J Gastroenterol 2009; 15: 1548-1553.